Research progress of aggressive B-cell lymphoma: reports from the 19th European Hematology Association annual congress
10.3760/cma.j.issn.1009-9921.2014.09.005
- VernacularTitle:侵袭性B细胞淋巴瘤研究进展:第19届欧洲血液学会年会报道
- Author:
Qi MIN
;
Huaqing WANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,B-cell,aggressive;
European Hematology Association annual congress
- From:
Journal of Leukemia & Lymphoma
2014;23(9):523-524
- CountryChina
- Language:Chinese
-
Abstract:
Aggressive B-cell lymphoma is characterized by malignant behaviour and rapid progression.Patients are prone to drug resistance or relapse of disease.The 19th European Hematology Association (EHA)annual congress explored several aspects about aggressive B-cell lymphoma.PET-CT examination provided new tools for the indication of prognosis.The elevated dose of rituximab improved the outcome of elderly male patients.Novel drugs or methods including bortezomib,ABT-199,combined targeted therapy and CNS prophylaxis have shown encouraging results in various clinical trials which provide new hope for patients with aggressive B-cell lymphoma.
